Inflammatory and Nested Testicular Sex Cord Tumors: Clinical and Molecular Characterization

A review of an ultra-rare testicular malignancy, defined by EWSR1::ATF1 gene fusions, that has been routinely misclassified as other tumor types

Journal: Genes | Published: 2026-03-19 | Type: Review | PMID: 41898873 Authors: Vlachostergios PJ et al. (University of Thessaly; IASO Thessalias Hospital, Greece) Funding/COI: Not listed

Summary

Inflammatory and nested testicular sex cord tumor (IN-TSCT) is a newly delineated malignant entity that has historically been mislabeled as Sertoli cell tumor (NOS) or seminoma. This Greek multi-institution review synthesizes the sparse published literature to define its molecular signature — recurrent EWSR1::ATF1 gene fusions, low tumor mutational burden — and its immunohistochemical profile. The upshot is that pathologists have almost certainly been getting this diagnosis wrong, and some patients may have received inappropriate management as a result.

Claims

• IN-TSCT is defined by recurrent EWSR1::ATF1 gene fusions, distinguishing it from other sex cord-stromal tumors
• Tumors express SF-1, inhibin, EMA, and CD30; germ cell markers are absent, which is the key to separating it from seminoma
• Growth pattern is solid and nested with epithelioid cells, hyalinized stroma, and conspicuous inflammatory infiltrate
• Tumor mutational burden is low, suggesting immunotherapy (which targets high-TMB tumors) is unlikely to be a useful approach
• A subset of cases showed metastatic spread, indicating potentially aggressive behavior — but the review does not provide a specific metastatic rate because the total case count is too small
• Typical presentation: unilateral, painless testicular enlargement; imaging findings are nonspecific

Study Quality

This is a narrative review, not a systematic review or meta-analysis, and it covers an entity with a very limited number of reported cases in the published literature. No sample size is provided for the aggregate case series; the abstract explicitly acknowledges that "the total number of reported cases remains very limited." There is no quantitative synthesis, no survival analysis, and no formal risk-of-bias assessment of the included cases. This is first-wave descriptive science — necessary groundwork, but far from definitive.

The journal Genes is a MDPI open-access publication. MDPI journals have variable peer-review rigor and are known to accept review articles rapidly. That does not invalidate the content, but it warrants noting.

Red Flags

• No case count given: the review never states how many total IN-TSCT cases exist in the literature — a critical omission for gauging the evidence base
• Funding and COI not disclosed: for a review that could influence clinical reclassification, this is a gap
• No systematic search methodology described in the abstract; likely a narrative review with attendant selection bias
• Metastatic risk unquantified: the claim that this tumor "may" metastasize is clinically important but unsupported by any reported rate
• MDPI/MDPI-adjacent publication speed may have compressed peer review

Strengths

• Fills a genuine gap: IN-TSCT is new enough that a consolidating review has real value for pathologists and urologists
• Clearly articulates the molecular hallmark (EWSR1::ATF1) that enables correct diagnosis going forward
• Practical immunohistochemical panel described (SF-1+, inhibin+, EMA+, CD30+, germ cell markers−) — actionable for diagnostic labs
• Addresses a misclassification problem with direct clinical consequences

Verdict

This paper is a useful reference document for a diagnosis that has almost certainly been missed or mislabeled in routine practice, but it is descriptive pathology at an early stage, not robust clinical evidence. The core contribution — EWSR1::ATF1 fusion defines a distinct, potentially aggressive tumor that is not seminoma and not Sertoli cell tumor NOS — is worth knowing. Everything else, especially the clinical behavior and prognosis, remains genuinely unknown. Read it as a flag to pathologists, not a guide to management.